nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC18A2—Parkinson's disease	0.277	0.357	CbGaD
Methamphetamine—MAOB—Parkinson's disease	0.19	0.245	CbGaD
Methamphetamine—MAOA—Parkinson's disease	0.133	0.172	CbGaD
Methamphetamine—SLC6A3—Parkinson's disease	0.115	0.148	CbGaD
Methamphetamine—CYP2D6—Parkinson's disease	0.0604	0.0779	CbGaD
Methamphetamine—SLC18A2—adrenal medulla—Parkinson's disease	0.00754	0.102	CbGeAlD
Methamphetamine—SLC6A2—locus ceruleus—Parkinson's disease	0.00387	0.0522	CbGeAlD
Methamphetamine—MAOA—locus ceruleus—Parkinson's disease	0.00357	0.0481	CbGeAlD
Methamphetamine—SLC6A2—sympathetic nervous system—Parkinson's disease	0.00306	0.0413	CbGeAlD
Methamphetamine—SLC18A2—telencephalic ventricle—Parkinson's disease	0.00301	0.0406	CbGeAlD
Methamphetamine—SLC6A3—telencephalic ventricle—Parkinson's disease	0.00228	0.0307	CbGeAlD
Methamphetamine—SLC6A2—autonomic nervous system—Parkinson's disease	0.00206	0.0277	CbGeAlD
Methamphetamine—SLC6A3—nerve—Parkinson's disease	0.00144	0.0193	CbGeAlD
Methamphetamine—SLC18A1—head—Parkinson's disease	0.00141	0.019	CbGeAlD
Methamphetamine—SLC18A1—nervous system—Parkinson's disease	0.00134	0.018	CbGeAlD
Methamphetamine—SLC22A3—tongue—Parkinson's disease	0.00132	0.0178	CbGeAlD
Methamphetamine—SLC18A1—central nervous system—Parkinson's disease	0.00129	0.0173	CbGeAlD
Methamphetamine—TAAR1—nervous system—Parkinson's disease	0.00126	0.0169	CbGeAlD
Methamphetamine—MAOB—nerve—Parkinson's disease	0.00125	0.0168	CbGeAlD
Methamphetamine—TAAR1—central nervous system—Parkinson's disease	0.00121	0.0163	CbGeAlD
Methamphetamine—SLC6A2—nerve—Parkinson's disease	0.00116	0.0156	CbGeAlD
Methamphetamine—SLC6A3—hindbrain—Parkinson's disease	0.00108	0.0145	CbGeAlD
Methamphetamine—MAOA—nerve—Parkinson's disease	0.00107	0.0144	CbGeAlD
Methamphetamine—ADRA2A—peripheral nervous system—Parkinson's disease	0.00105	0.0141	CbGeAlD
Methamphetamine—SLC18A1—brain—Parkinson's disease	0.00102	0.0138	CbGeAlD
Methamphetamine—SLC6A4—hindbrain—Parkinson's disease	0.000985	0.0133	CbGeAlD
Methamphetamine—MAOB—hindbrain—Parkinson's disease	0.000937	0.0126	CbGeAlD
Methamphetamine—SLC18A2—brainstem—Parkinson's disease	0.000815	0.011	CbGeAlD
Methamphetamine—MAOA—hindbrain—Parkinson's disease	0.000799	0.0108	CbGeAlD
Methamphetamine—SLC18A2—forebrain—Parkinson's disease	0.000786	0.0106	CbGeAlD
Methamphetamine—SLC22A3—embryo—Parkinson's disease	0.000633	0.00853	CbGeAlD
Methamphetamine—SLC6A3—brainstem—Parkinson's disease	0.000616	0.0083	CbGeAlD
Methamphetamine—SLC6A3—forebrain—Parkinson's disease	0.000595	0.00801	CbGeAlD
Methamphetamine—MAOB—embryo—Parkinson's disease	0.000586	0.00789	CbGeAlD
Methamphetamine—SLC18A2—medulla oblongata—Parkinson's disease	0.000568	0.00765	CbGeAlD
Methamphetamine—SLC6A4—brainstem—Parkinson's disease	0.000565	0.00761	CbGeAlD
Methamphetamine—Isocarboxazid—MAOB—Parkinson's disease	0.000546	0.0787	CrCbGaD
Methamphetamine—SLC6A4—forebrain—Parkinson's disease	0.000545	0.00734	CbGeAlD
Methamphetamine—MAOB—brainstem—Parkinson's disease	0.000537	0.00723	CbGeAlD
Methamphetamine—SLC18A2—midbrain—Parkinson's disease	0.000519	0.00699	CbGeAlD
Methamphetamine—MAOB—forebrain—Parkinson's disease	0.000518	0.00698	CbGeAlD
Methamphetamine—MAOA—embryo—Parkinson's disease	0.0005	0.00673	CbGeAlD
Methamphetamine—SLC6A2—brainstem—Parkinson's disease	0.000497	0.0067	CbGeAlD
Methamphetamine—SLC6A2—forebrain—Parkinson's disease	0.00048	0.00646	CbGeAlD
Methamphetamine—CYP2D6—hindbrain—Parkinson's disease	0.000475	0.0064	CbGeAlD
Methamphetamine—MAOA—brainstem—Parkinson's disease	0.000458	0.00617	CbGeAlD
Methamphetamine—SLC18A2—head—Parkinson's disease	0.00045	0.00606	CbGeAlD
Methamphetamine—Lisdexamfetamine—SLC18A2—Parkinson's disease	0.000442	0.0638	CrCbGaD
Methamphetamine—MAOA—forebrain—Parkinson's disease	0.000442	0.00596	CbGeAlD
Methamphetamine—MAOB—cardiovascular system—Parkinson's disease	0.000438	0.0059	CbGeAlD
Methamphetamine—SLC18A2—nervous system—Parkinson's disease	0.000427	0.00575	CbGeAlD
Methamphetamine—SLC18A2—central nervous system—Parkinson's disease	0.000411	0.00554	CbGeAlD
Methamphetamine—SLC18A2—cerebellum—Parkinson's disease	0.000402	0.00541	CbGeAlD
Methamphetamine—SLC6A3—midbrain—Parkinson's disease	0.000393	0.00529	CbGeAlD
Methamphetamine—SLC6A3—spinal cord—Parkinson's disease	0.000383	0.00516	CbGeAlD
Methamphetamine—Isocarboxazid—MAOA—Parkinson's disease	0.000383	0.0552	CrCbGaD
Methamphetamine—MAOB—medulla oblongata—Parkinson's disease	0.000374	0.00504	CbGeAlD
Methamphetamine—MAOA—cardiovascular system—Parkinson's disease	0.000374	0.00504	CbGeAlD
Methamphetamine—SLC6A4—midbrain—Parkinson's disease	0.00036	0.00485	CbGeAlD
Methamphetamine—Pargyline—MAOB—Parkinson's disease	0.000352	0.0507	CrCbGaD
Methamphetamine—SLC6A4—spinal cord—Parkinson's disease	0.000351	0.00473	CbGeAlD
Methamphetamine—SLC6A2—medulla oblongata—Parkinson's disease	0.000347	0.00467	CbGeAlD
Methamphetamine—Ephedrine—SLC18A2—Parkinson's disease	0.000346	0.0499	CrCbGaD
Methamphetamine—MAOB—midbrain—Parkinson's disease	0.000342	0.00461	CbGeAlD
Methamphetamine—SLC6A3—head—Parkinson's disease	0.000341	0.00459	CbGeAlD
Methamphetamine—ADRA2A—forebrain—Parkinson's disease	0.000339	0.00457	CbGeAlD
Methamphetamine—MAOB—spinal cord—Parkinson's disease	0.000334	0.0045	CbGeAlD
Methamphetamine—SLC18A2—brain—Parkinson's disease	0.000326	0.00439	CbGeAlD
Methamphetamine—SLC6A3—nervous system—Parkinson's disease	0.000323	0.00435	CbGeAlD
Methamphetamine—SLC22A3—head—Parkinson's disease	0.000321	0.00432	CbGeAlD
Methamphetamine—MAOA—medulla oblongata—Parkinson's disease	0.000319	0.0043	CbGeAlD
Methamphetamine—SLC6A4—head—Parkinson's disease	0.000312	0.0042	CbGeAlD
Methamphetamine—SLC6A3—central nervous system—Parkinson's disease	0.000311	0.00419	CbGeAlD
Methamphetamine—ADRA2C—medulla oblongata—Parkinson's disease	0.000307	0.00414	CbGeAlD
Methamphetamine—SLC22A3—nervous system—Parkinson's disease	0.000304	0.00409	CbGeAlD
Methamphetamine—SLC6A3—cerebellum—Parkinson's disease	0.000304	0.00409	CbGeAlD
Methamphetamine—MAOB—head—Parkinson's disease	0.000297	0.004	CbGeAlD
Methamphetamine—SLC6A4—nervous system—Parkinson's disease	0.000296	0.00399	CbGeAlD
Methamphetamine—SLC22A5—medulla oblongata—Parkinson's disease	0.000294	0.00396	CbGeAlD
Methamphetamine—SLC22A3—central nervous system—Parkinson's disease	0.000293	0.00394	CbGeAlD
Methamphetamine—MAOA—midbrain—Parkinson's disease	0.000292	0.00393	CbGeAlD
Methamphetamine—SLC6A4—central nervous system—Parkinson's disease	0.000285	0.00384	CbGeAlD
Methamphetamine—MAOA—spinal cord—Parkinson's disease	0.000285	0.00384	CbGeAlD
Methamphetamine—MAOB—nervous system—Parkinson's disease	0.000281	0.00379	CbGeAlD
Methamphetamine—ADRA2C—midbrain—Parkinson's disease	0.000281	0.00378	CbGeAlD
Methamphetamine—SLC6A2—head—Parkinson's disease	0.000275	0.0037	CbGeAlD
Methamphetamine—ADRA2C—spinal cord—Parkinson's disease	0.000274	0.00369	CbGeAlD
Methamphetamine—CYP2D6—brainstem—Parkinson's disease	0.000272	0.00367	CbGeAlD
Methamphetamine—MAOB—central nervous system—Parkinson's disease	0.000271	0.00365	CbGeAlD
Methamphetamine—SLC22A5—midbrain—Parkinson's disease	0.000269	0.00362	CbGeAlD
Methamphetamine—MAOB—cerebellum—Parkinson's disease	0.000265	0.00357	CbGeAlD
Methamphetamine—Dextroamphetamine—SLC18A2—Parkinson's disease	0.000264	0.0381	CrCbGaD
Methamphetamine—CYP2D6—forebrain—Parkinson's disease	0.000263	0.00354	CbGeAlD
Methamphetamine—SLC22A5—spinal cord—Parkinson's disease	0.000262	0.00353	CbGeAlD
Methamphetamine—SLC6A2—nervous system—Parkinson's disease	0.00026	0.00351	CbGeAlD
Methamphetamine—MAOA—head—Parkinson's disease	0.000253	0.00341	CbGeAlD
Methamphetamine—SLC6A2—central nervous system—Parkinson's disease	0.000251	0.00338	CbGeAlD
Methamphetamine—L-Phenylalanine—TH—Parkinson's disease	0.000249	0.0359	CrCbGaD
Methamphetamine—SLC6A3—brain—Parkinson's disease	0.000247	0.00332	CbGeAlD
Methamphetamine—Pargyline—MAOA—Parkinson's disease	0.000246	0.0356	CrCbGaD
Methamphetamine—ADRA2A—medulla oblongata—Parkinson's disease	0.000245	0.0033	CbGeAlD
Methamphetamine—ADRA2C—head—Parkinson's disease	0.000243	0.00328	CbGeAlD
Methamphetamine—Diethylpropion—SLC6A3—Parkinson's disease	0.000242	0.0349	CrCbGaD
Methamphetamine—MAOA—nervous system—Parkinson's disease	0.00024	0.00323	CbGeAlD
Methamphetamine—SLC22A3—brain—Parkinson's disease	0.000232	0.00313	CbGeAlD
Methamphetamine—MAOA—central nervous system—Parkinson's disease	0.000231	0.00311	CbGeAlD
Methamphetamine—ADRA2C—nervous system—Parkinson's disease	0.000231	0.00311	CbGeAlD
Methamphetamine—SLC6A4—brain—Parkinson's disease	0.000226	0.00305	CbGeAlD
Methamphetamine—MAOA—cerebellum—Parkinson's disease	0.000226	0.00304	CbGeAlD
Methamphetamine—ADRA2A—midbrain—Parkinson's disease	0.000224	0.00302	CbGeAlD
Methamphetamine—ADRA2C—central nervous system—Parkinson's disease	0.000222	0.00299	CbGeAlD
Methamphetamine—ADRA2A—spinal cord—Parkinson's disease	0.000219	0.00294	CbGeAlD
Methamphetamine—ADRA2C—cerebellum—Parkinson's disease	0.000217	0.00293	CbGeAlD
Methamphetamine—MAOB—brain—Parkinson's disease	0.000215	0.0029	CbGeAlD
Methamphetamine—Amphetamine—SLC18A2—Parkinson's disease	0.000213	0.0307	CrCbGaD
Methamphetamine—SLC22A5—cerebellum—Parkinson's disease	0.000208	0.0028	CbGeAlD
Methamphetamine—SLC6A2—brain—Parkinson's disease	0.000199	0.00268	CbGeAlD
Methamphetamine—Benzphetamine—SLC18A2—Parkinson's disease	0.000196	0.0282	CrCbGaD
Methamphetamine—ADRA2A—head—Parkinson's disease	0.000194	0.00262	CbGeAlD
Methamphetamine—Phentermine—MAOB—Parkinson's disease	0.00019	0.0274	CrCbGaD
Methamphetamine—ADRA2A—nervous system—Parkinson's disease	0.000184	0.00248	CbGeAlD
Methamphetamine—Lisdexamfetamine—SLC6A3—Parkinson's disease	0.000183	0.0265	CrCbGaD
Methamphetamine—MAOA—brain—Parkinson's disease	0.000183	0.00247	CbGeAlD
Methamphetamine—ADRA2A—central nervous system—Parkinson's disease	0.000177	0.00239	CbGeAlD
Methamphetamine—ADRA2C—brain—Parkinson's disease	0.000176	0.00238	CbGeAlD
Methamphetamine—Selegiline—MAOB—Parkinson's disease	0.000176	0.0253	CrCbGaD
Methamphetamine—ADRA2A—cerebellum—Parkinson's disease	0.000173	0.00233	CbGeAlD
Methamphetamine—Dexfenfluramine—CYP2E1—Parkinson's disease	0.000171	0.0246	CrCbGaD
Methamphetamine—SLC22A5—brain—Parkinson's disease	0.000169	0.00228	CbGeAlD
Methamphetamine—Phenelzine—MAOB—Parkinson's disease	0.000155	0.0223	CrCbGaD
Methamphetamine—CYP2D6—head—Parkinson's disease	0.00015	0.00203	CbGeAlD
Methamphetamine—Phenylpropanolamine—MAOA—Parkinson's disease	0.000149	0.0215	CrCbGaD
Methamphetamine—Amphetamine—MAOB—Parkinson's disease	0.000146	0.0211	CrCbGaD
Methamphetamine—CYP2D6—nervous system—Parkinson's disease	0.000143	0.00192	CbGeAlD
Methamphetamine—ADRA2A—brain—Parkinson's disease	0.000141	0.0019	CbGeAlD
Methamphetamine—CYP2D6—central nervous system—Parkinson's disease	0.000137	0.00185	CbGeAlD
Methamphetamine—Phenylpropanolamine—DRD1—Parkinson's disease	0.000136	0.0196	CrCbGaD
Methamphetamine—CYP2D6—cerebellum—Parkinson's disease	0.000134	0.00181	CbGeAlD
Methamphetamine—Phentermine—MAOA—Parkinson's disease	0.000133	0.0192	CrCbGaD
Methamphetamine—Phenylpropanolamine—SLC6A3—Parkinson's disease	0.000129	0.0186	CrCbGaD
Methamphetamine—Pseudoephedrine—MAOA—Parkinson's disease	0.000126	0.0182	CrCbGaD
Methamphetamine—Dexfenfluramine—CYP2D6—Parkinson's disease	0.000125	0.0181	CrCbGaD
Methamphetamine—Selegiline—MAOA—Parkinson's disease	0.000123	0.0178	CrCbGaD
Methamphetamine—Phentermine—SLC6A3—Parkinson's disease	0.000115	0.0166	CrCbGaD
Methamphetamine—Dextroamphetamine—SLC6A3—Parkinson's disease	0.000109	0.0158	CrCbGaD
Methamphetamine—CYP2D6—brain—Parkinson's disease	0.000109	0.00147	CbGeAlD
Methamphetamine—Pseudoephedrine—SLC6A3—Parkinson's disease	0.000109	0.0157	CrCbGaD
Methamphetamine—Phenelzine—MAOA—Parkinson's disease	0.000109	0.0157	CrCbGaD
Methamphetamine—Pseudoephedrine—TNF—Parkinson's disease	0.000101	0.0146	CrCbGaD
Methamphetamine—Amphetamine—SLC6A3—Parkinson's disease	8.82e-05	0.0127	CrCbGaD
Methamphetamine—Phenformin—CYP2D6—Parkinson's disease	8.82e-05	0.0127	CrCbGaD
Methamphetamine—Benzphetamine—SLC6A3—Parkinson's disease	8.11e-05	0.0117	CrCbGaD
Methamphetamine—Benzyl alcohol—CYP2E1—Parkinson's disease	7.92e-05	0.0114	CrCbGaD
Methamphetamine—Selegiline—CYP2E1—Parkinson's disease	7.6e-05	0.011	CrCbGaD
Methamphetamine—Phenelzine—CYP2E1—Parkinson's disease	6.7e-05	0.00966	CrCbGaD
Methamphetamine—Amphetamine—DRD2—Parkinson's disease	6.56e-05	0.00947	CrCbGaD
Methamphetamine—Phentermine—CYP2D6—Parkinson's disease	6.03e-05	0.0087	CrCbGaD
Methamphetamine—Benzyl alcohol—CYP2D6—Parkinson's disease	5.82e-05	0.00839	CrCbGaD
Methamphetamine—Dextroamphetamine—CYP2D6—Parkinson's disease	5.75e-05	0.0083	CrCbGaD
Methamphetamine—Pseudoephedrine—CYP2D6—Parkinson's disease	5.72e-05	0.00825	CrCbGaD
Methamphetamine—Selegiline—CYP2D6—Parkinson's disease	5.58e-05	0.00805	CrCbGaD
Methamphetamine—Nateglinide—CYP2D6—Parkinson's disease	4.99e-05	0.0072	CrCbGaD
Methamphetamine—Amphetamine—CYP2D6—Parkinson's disease	4.64e-05	0.00669	CrCbGaD
Methamphetamine—Selegiline—ABCB1—Parkinson's disease	3.99e-05	0.00575	CrCbGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—DRD1—Parkinson's disease	1.48e-05	0.000103	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—GRM4—Parkinson's disease	1.48e-05	0.000103	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SOD1—Parkinson's disease	1.47e-05	0.000103	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—TAC1—Parkinson's disease	1.47e-05	0.000103	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ND3—Parkinson's disease	1.45e-05	0.000101	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MCCC1—Parkinson's disease	1.45e-05	0.000101	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—DRD1—Parkinson's disease	1.44e-05	0.000101	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—ADORA2A—Parkinson's disease	1.44e-05	0.0001	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—DRD3—Parkinson's disease	1.44e-05	0.0001	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSTA4—Parkinson's disease	1.44e-05	0.0001	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—ADRBK1—Parkinson's disease	1.44e-05	0.0001	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CYP2E1—Parkinson's disease	1.43e-05	9.95e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—NQO1—Parkinson's disease	1.41e-05	9.84e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PENK—Parkinson's disease	1.41e-05	9.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAG—Parkinson's disease	1.41e-05	9.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—ABL1—Parkinson's disease	1.41e-05	9.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IGF2—Parkinson's disease	1.4e-05	9.76e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—COMT—Parkinson's disease	1.4e-05	9.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—DRD3—Parkinson's disease	1.4e-05	9.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HTR1A—Parkinson's disease	1.4e-05	9.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—DRD2—Parkinson's disease	1.39e-05	9.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—HTR7—Parkinson's disease	1.39e-05	9.7e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GSTP1—Parkinson's disease	1.39e-05	9.7e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—TH—Parkinson's disease	1.39e-05	9.7e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—MAOA—Parkinson's disease	1.39e-05	9.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GRM4—Parkinson's disease	1.39e-05	9.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—TAC1—Parkinson's disease	1.37e-05	9.58e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—HMOX1—Parkinson's disease	1.37e-05	9.57e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—OMD—Parkinson's disease	1.36e-05	9.49e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TALDO1—Parkinson's disease	1.36e-05	9.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—DRD1—Parkinson's disease	1.35e-05	9.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—ADRBK1—Parkinson's disease	1.34e-05	9.36e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CYCS—Parkinson's disease	1.34e-05	9.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RIT2—Parkinson's disease	1.32e-05	9.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—HGF—Parkinson's disease	1.32e-05	9.22e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—ABCB1—Parkinson's disease	1.32e-05	9.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PENK—Parkinson's disease	1.31e-05	9.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAG—Parkinson's disease	1.31e-05	9.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—HTR2A—Parkinson's disease	1.31e-05	9.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—ADORA2A—Parkinson's disease	1.31e-05	9.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—DRD3—Parkinson's disease	1.31e-05	9.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—ADRBK1—Parkinson's disease	1.3e-05	9.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—DRD2—Parkinson's disease	1.3e-05	9.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—HTR7—Parkinson's disease	1.3e-05	9.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PLA2G6—Parkinson's disease	1.29e-05	9.02e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NDUFB11—Parkinson's disease	1.29e-05	9e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PDYN—Parkinson's disease	1.29e-05	8.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—MAOB—Parkinson's disease	1.28e-05	8.93e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GSTM1—Parkinson's disease	1.28e-05	8.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—DRD2—Parkinson's disease	1.26e-05	8.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HTR7—Parkinson's disease	1.26e-05	8.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GRK5—Parkinson's disease	1.26e-05	8.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—HTR1A—Parkinson's disease	1.25e-05	8.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—DDC—Parkinson's disease	1.24e-05	8.62e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GCH1—Parkinson's disease	1.23e-05	8.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—TAC1—Parkinson's disease	1.23e-05	8.57e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GPX1—Parkinson's disease	1.22e-05	8.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—ADRBK1—Parkinson's disease	1.22e-05	8.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—GFAP—Parkinson's disease	1.21e-05	8.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—DRD1—Parkinson's disease	1.21e-05	8.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PDYN—Parkinson's disease	1.2e-05	8.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—GRM5—Parkinson's disease	1.2e-05	8.34e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—COMT—Parkinson's disease	1.18e-05	8.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—DRD2—Parkinson's disease	1.18e-05	8.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HTR7—Parkinson's disease	1.18e-05	8.23e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GSTP1—Parkinson's disease	1.18e-05	8.21e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—MAOA—Parkinson's disease	1.17e-05	8.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—DRD3—Parkinson's disease	1.17e-05	8.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTA4—Parkinson's disease	1.17e-05	8.14e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—HMOX1—Parkinson's disease	1.16e-05	8.09e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CYP2D6—Parkinson's disease	1.16e-05	8.07e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CTGF—Parkinson's disease	1.14e-05	7.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HTR1A—Parkinson's disease	1.13e-05	7.9e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—MTHFR—Parkinson's disease	1.13e-05	7.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GFAP—Parkinson's disease	1.13e-05	7.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GRM4—Parkinson's disease	1.13e-05	7.85e-05	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CASP3—Parkinson's disease	1.12e-05	7.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GRM5—Parkinson's disease	1.12e-05	7.79e-05	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—IL6—Parkinson's disease	1.12e-05	7.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—TAC1—Parkinson's disease	1.12e-05	7.78e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—ABCB1—Parkinson's disease	1.11e-05	7.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—EDN1—Parkinson's disease	1.11e-05	7.77e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GBA—Parkinson's disease	1.1e-05	7.65e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—FBP1—Parkinson's disease	1.1e-05	7.65e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—DBH—Parkinson's disease	1.1e-05	7.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—DRD1—Parkinson's disease	1.09e-05	7.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—ADRBK1—Parkinson's disease	1.09e-05	7.6e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GSTM1—Parkinson's disease	1.08e-05	7.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PENK—Parkinson's disease	1.07e-05	7.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAG—Parkinson's disease	1.07e-05	7.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—DRD3—Parkinson's disease	1.06e-05	7.39e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CYP2E1—Parkinson's disease	1.06e-05	7.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—DRD2—Parkinson's disease	1.06e-05	7.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—HTR7—Parkinson's disease	1.06e-05	7.36e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—APOE—Parkinson's disease	1.05e-05	7.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PLA2G6—Parkinson's disease	1.05e-05	7.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FGF20—Parkinson's disease	1.05e-05	7.31e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—NQO1—Parkinson's disease	1.05e-05	7.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—EDN1—Parkinson's disease	1.04e-05	7.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—MAOB—Parkinson's disease	1.04e-05	7.25e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GPX1—Parkinson's disease	1.04e-05	7.22e-05	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—MAPK8—Parkinson's disease	1.03e-05	7.2e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—TH—Parkinson's disease	1.03e-05	7.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ADORA2A—Parkinson's disease	1.02e-05	7.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—EDN1—Parkinson's disease	1.01e-05	7.05e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CYCS—Parkinson's disease	9.9e-06	6.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—ADRBK1—Parkinson's disease	9.9e-06	6.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FGF20—Parkinson's disease	9.8e-06	6.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PDYN—Parkinson's disease	9.76e-06	6.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—HTR2A—Parkinson's disease	9.75e-06	6.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HTR7—Parkinson's disease	9.59e-06	6.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—DRD2—Parkinson's disease	9.59e-06	6.68e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—MTHFR—Parkinson's disease	9.56e-06	6.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CYP2D6—Parkinson's disease	9.52e-06	6.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ADORA2A—Parkinson's disease	9.5e-06	6.62e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—EDN1—Parkinson's disease	9.45e-06	6.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—INSR—Parkinson's disease	9.39e-06	6.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CTGF—Parkinson's disease	9.34e-06	6.52e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GFAP—Parkinson's disease	9.18e-06	6.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—HTR2A—Parkinson's disease	9.1e-06	6.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GRM5—Parkinson's disease	9.07e-06	6.33e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—INS—Parkinson's disease	8.99e-06	6.27e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—APOE—Parkinson's disease	8.9e-06	6.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FGB—Parkinson's disease	8.87e-06	6.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HTR2A—Parkinson's disease	8.85e-06	6.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HTR1A—Parkinson's disease	8.82e-06	6.15e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—COMT—Parkinson's disease	8.77e-06	6.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—INSR—Parkinson's disease	8.77e-06	6.11e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GSTP1—Parkinson's disease	8.73e-06	6.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CYP2E1—Parkinson's disease	8.71e-06	6.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TAC1—Parkinson's disease	8.69e-06	6.06e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—HMOX1—Parkinson's disease	8.61e-06	6e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NQO1—Parkinson's disease	8.61e-06	6e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—DRD1—Parkinson's disease	8.52e-06	5.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—TH—Parkinson's disease	8.49e-06	5.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—EDN1—Parkinson's disease	8.45e-06	5.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FGB—Parkinson's disease	8.29e-06	5.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HTR2A—Parkinson's disease	8.27e-06	5.76e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ABCB1—Parkinson's disease	8.26e-06	5.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—DRD3—Parkinson's disease	8.25e-06	5.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HTR1A—Parkinson's disease	8.24e-06	5.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CYCS—Parkinson's disease	8.15e-06	5.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TAC1—Parkinson's disease	8.12e-06	5.66e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—DDC—Parkinson's disease	8.05e-06	5.62e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GSTM1—Parkinson's disease	8.02e-06	5.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—DRD1—Parkinson's disease	7.96e-06	5.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGF20—Parkinson's disease	7.96e-06	5.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYP2D6—Parkinson's disease	7.73e-06	5.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ADORA2A—Parkinson's disease	7.72e-06	5.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—DRD3—Parkinson's disease	7.71e-06	5.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ADRBK1—Parkinson's disease	7.71e-06	5.37e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GPX1—Parkinson's disease	7.68e-06	5.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—EDN1—Parkinson's disease	7.68e-06	5.35e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTA4—Parkinson's disease	7.61e-06	5.3e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—INS—Parkinson's disease	7.6e-06	5.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CTGF—Parkinson's disease	7.59e-06	5.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HTR7—Parkinson's disease	7.46e-06	5.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—DRD2—Parkinson's disease	7.46e-06	5.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—HTR2A—Parkinson's disease	7.39e-06	5.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—COMT—Parkinson's disease	7.22e-06	5.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ADRBK1—Parkinson's disease	7.2e-06	5.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSTP1—Parkinson's disease	7.18e-06	5.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—MAOA—Parkinson's disease	7.16e-06	4.99e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—INSR—Parkinson's disease	7.12e-06	4.96e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—MTHFR—Parkinson's disease	7.09e-06	4.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—HMOX1—Parkinson's disease	7.08e-06	4.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYP2E1—Parkinson's disease	7.07e-06	4.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NQO1—Parkinson's disease	6.99e-06	4.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HTR7—Parkinson's disease	6.97e-06	4.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—DRD2—Parkinson's disease	6.97e-06	4.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—TH—Parkinson's disease	6.89e-06	4.81e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	6.85e-06	4.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ABCB1—Parkinson's disease	6.8e-06	4.74e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MAOB—Parkinson's disease	6.78e-06	4.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGB—Parkinson's disease	6.73e-06	4.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HTR2A—Parkinson's disease	6.71e-06	4.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HTR1A—Parkinson's disease	6.69e-06	4.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYCS—Parkinson's disease	6.62e-06	4.61e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—APOE—Parkinson's disease	6.6e-06	4.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSTM1—Parkinson's disease	6.6e-06	4.6e-05	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL6—Parkinson's disease	6.59e-06	4.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TAC1—Parkinson's disease	6.59e-06	4.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—DRD1—Parkinson's disease	6.47e-06	4.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GPX1—Parkinson's disease	6.32e-06	4.41e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—DRD3—Parkinson's disease	6.26e-06	4.37e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IGF2—Parkinson's disease	6.26e-06	4.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IGF1R—Parkinson's disease	6.05e-06	4.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EDN1—Parkinson's disease	5.98e-06	4.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—COMT—Parkinson's disease	5.86e-06	4.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ADRBK1—Parkinson's disease	5.85e-06	4.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IGF2—Parkinson's disease	5.84e-06	4.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTP1—Parkinson's disease	5.83e-06	4.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—MTHFR—Parkinson's disease	5.83e-06	4.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—MAOA—Parkinson's disease	5.82e-06	4.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—HMOX1—Parkinson's disease	5.75e-06	4.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—DRD2—Parkinson's disease	5.66e-06	3.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HTR7—Parkinson's disease	5.66e-06	3.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IGF1R—Parkinson's disease	5.65e-06	3.94e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—INS—Parkinson's disease	5.64e-06	3.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EDN1—Parkinson's disease	5.58e-06	3.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ABCB1—Parkinson's disease	5.52e-06	3.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NGF—Parkinson's disease	5.49e-06	3.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—APOE—Parkinson's disease	5.43e-06	3.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTM1—Parkinson's disease	5.36e-06	3.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HTR2A—Parkinson's disease	5.23e-06	3.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GPX1—Parkinson's disease	5.13e-06	3.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NGF—Parkinson's disease	5.13e-06	3.58e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CTGF—Parkinson's disease	4.95e-06	3.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HTR2A—Parkinson's disease	4.88e-06	3.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APOE—Parkinson's disease	4.86e-06	3.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF2—Parkinson's disease	4.75e-06	3.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—MTHFR—Parkinson's disease	4.74e-06	3.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—INS—Parkinson's disease	4.64e-06	3.23e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	4.61e-06	3.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1R—Parkinson's disease	4.59e-06	3.2e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NQO1—Parkinson's disease	4.56e-06	3.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APOE—Parkinson's disease	4.54e-06	3.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EDN1—Parkinson's disease	4.53e-06	3.16e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TH—Parkinson's disease	4.49e-06	3.13e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—APOE—Parkinson's disease	4.41e-06	3.07e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYCS—Parkinson's disease	4.31e-06	3.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NGF—Parkinson's disease	4.17e-06	2.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—INS—Parkinson's disease	4.15e-06	2.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HTR2A—Parkinson's disease	3.97e-06	2.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—INS—Parkinson's disease	3.88e-06	2.7e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—COMT—Parkinson's disease	3.82e-06	2.66e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTP1—Parkinson's disease	3.8e-06	2.65e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MAOA—Parkinson's disease	3.79e-06	2.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—INS—Parkinson's disease	3.77e-06	2.63e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HMOX1—Parkinson's disease	3.75e-06	2.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APOE—Parkinson's disease	3.69e-06	2.57e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ABCB1—Parkinson's disease	3.6e-06	2.51e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTM1—Parkinson's disease	3.49e-06	2.44e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GPX1—Parkinson's disease	3.34e-06	2.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—INS—Parkinson's disease	3.15e-06	2.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CASP3—Parkinson's disease	3.09e-06	2.16e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MTHFR—Parkinson's disease	3.09e-06	2.15e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—Parkinson's disease	3.07e-06	2.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CASP3—Parkinson's disease	2.89e-06	2.01e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOE—Parkinson's disease	2.87e-06	2e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—Parkinson's disease	2.87e-06	2e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAPK8—Parkinson's disease	2.84e-06	1.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAPK8—Parkinson's disease	2.65e-06	1.85e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—INS—Parkinson's disease	2.45e-06	1.71e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CASP3—Parkinson's disease	2.35e-06	1.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—Parkinson's disease	2.33e-06	1.62e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAPK8—Parkinson's disease	2.16e-06	1.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—Parkinson's disease	1.81e-06	1.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—Parkinson's disease	1.69e-06	1.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—Parkinson's disease	1.38e-06	9.6e-06	CbGpPWpGaD
